Therapeutic response of benzodiazepine, orphenadrine citrate and occlusal splint association in TMD pain

Página do item simplificado
dc.contributor.authorRizzatti-Barbosa, Célia M.
dc.contributor.authorMartinelli, Denise A.
dc.contributor.authorAmbrosano, Gláucia M. B.
dc.contributor.authorDe Albergaria-Barbosa, José R. [UNESP]
dc.contributor.institutionDept. de Protese e Periodontia
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionIntl. Assoc. for the Study of Pain
dc.contributor.institutionIntl. Assoc. for Dental Research
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)
dc.contributor.institutionBrazilian Soc. for Dental Research
dc.contributor.institutionInternational Biometric Society
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionA. C. Camargo Cancer Center
dc.date.accessioned2014-05-27T11:20:38Z
dc.date.available2014-05-27T11:20:38Z
dc.date.issued2003-04-01
dc.description.abstractLoss of function, muscle inflammation, and pain are some of the signs and symptoms of temporomandibular dysfunction (TMD). Pharmacological strategies to minimize the clinical manifestation of these disorders often focus on blocking or inhibiting the pain-causing symptom. Resources such as muscle-relaxants, anxiety-relief drugs, and splint therapy are often used to reduce muscular hyperactivity related to TMD muscle pain. This study compares the effect of a randomly ordered association of occlusal splint therapy (S), nonsteroid anti-inflammatory with a muscle-relaxant drug (orphenadrine citrate) (O), and an anxiety-relief drug (benzodiazepine) (B), to ease painful TMD muscle symptoms. Clinical and anamnestic analyses were recorded in accordance with the Helkimo TMD index and applied before and after treatments. Twenty-one group two Helkimo TMD adult female patients were treated, all of whom were subjected to the three random therapeutic associations proposed: SBO, BOS, and OSB. The same operator applied the three specific associations over a period of 21 days in the proposed sequence, seven days for each therapy. The results show that all the groups presented the best results in terms of relief from pain after the therapeutic association (28.5% showed a decrease and 47.6% showed an absence of symptoms). No significant difference was observed among association therapeutic protocols. Copyright © 2003 by CHROMA, Inc.en
dc.description.affiliationFaculty of Odontologia de Piracicaba Dept. de Protese e Periodontia, Ave. Limeira, 901 Bairro Areiao, CEP 13414.900 Piracicaba, SP
dc.description.affiliationState University of São Paulo
dc.description.affiliationIntl. Assoc. for the Study of Pain
dc.description.affiliationIntl. Assoc. for Dental Research
dc.description.affiliationState University of Campinas
dc.description.affiliationBrazilian Soc. for Dental Research
dc.description.affiliationInternational Biometric Society
dc.description.affiliationJulio Mesquita Filho State U.
dc.description.affiliationA. C. Camargo Hospital, São Paulo
dc.description.affiliationDept. of Oral Medicine of UNICAMP
dc.description.affiliationDent. Clin. UNICAMP Dent. Coll.
dc.description.affiliationUnespJulio Mesquita Filho State U.
dc.format.extent116-120
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/12723857
dc.identifier.citationCranio, v. 21, n. 2, p. 116-120, 2003.
dc.identifier.issn0886-9634
dc.identifier.lattes1664688357804299
dc.identifier.scopus2-s2.0-0038166511
dc.identifier.urihttp://hdl.handle.net/11449/67256
dc.language.isoeng
dc.relation.ispartofCranio
dc.relation.ispartofjcr1.094
dc.relation.ispartofsjr0,374
dc.rights.accessRightsAcesso restrito
dc.sourceScopus
dc.subjectanxiolytic agent
dc.subjectbenzodiazepine derivative
dc.subjectcentral muscle relaxant
dc.subjectnonsteroid antiinflammatory agent
dc.subjectorphenadrine
dc.subjectbenzodiazepine
dc.subjectmuscle relaxant agent
dc.subjectorphenadrine citrate
dc.subjectadult
dc.subjectclinical protocol
dc.subjectclinical trial
dc.subjectcomparative study
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdental equipment
dc.subjectdrug effect
dc.subjectface pain
dc.subjectfemale
dc.subjectfollow up
dc.subjecthuman
dc.subjectmasticatory muscle
dc.subjectnonparametric test
dc.subjectrandomized controlled trial
dc.subjecttemporomandibular joint disorder
dc.subjectanamnesis
dc.subjectclinical article
dc.subjectclinical feature
dc.subjectdrug response
dc.subjectmyofascial pain
dc.subjectstatistical significance
dc.subjectAdult
dc.subjectAnti-Anxiety Agents
dc.subjectAnti-Inflammatory Agents, Non-Steroidal
dc.subjectBenzodiazepines
dc.subjectClinical Protocols
dc.subjectFacial Pain
dc.subjectFemale
dc.subjectFollow-Up Studies
dc.subjectHumans
dc.subjectMasticatory Muscles
dc.subjectMuscle Relaxants, Central
dc.subjectOcclusal Splints
dc.subjectOrphenadrine
dc.subjectStatistics, Nonparametric
dc.subjectTemporomandibular Joint Disorders
dc.titleTherapeutic response of benzodiazepine, orphenadrine citrate and occlusal splint association in TMD painen
dc.typeArtigo
unesp.author.lattes1664688357804299
unesp.campusUniversidade Estadual Paulista (Unesp), Instituto de Ciência e Tecnologia, São José dos Campospt

Arquivos

Coleções

Artigos - Biociências e Diagnóstico Bucal - ICT